(2R,4R)-4-((tert-Butoxycarbonyl)amino)-2-hydroxy-2,6-dimethyl-3-oxoheptyl Acetate is an intermediate in the synthesis of Carfilzomib (2R,4R)-Diol (C183525), which is a derivative of Carflizomib (C183460), a second-generation proteasome inhibitor that is used as a treatment in relapsed and refractory multiple myeloma.